Kosti A, Barreiro R, Guardia GDA, Ostadrahimi S, Kokovay E, Pertsemlidis A, Galante PAF ,Penalva LOF. Synergism of proneurogenic miRNAs provides a more effective strategy to target glioma stem cells. Cancers 2021;13(2):289.
Moroney JB, Vasudev A, Pertsemlidis A, Zan H, Casali P. Integrative transcriptome and chromatin landscape analysis reveals distinct epigenetic regulations in human memory B cells. Nature Communications 2020;11(1):5435.
Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. 5GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing Sarcoma. International Journal of Cancer 2020;146(11):3184-3195.
Kosti A, Du L, Shivram H, Qiao M, Burns S, Garcia JG, PertsemlidisA, Iyer V, Kokovay E, Penalva LO. ELF4 is a target of miR-124 and promotes neuroblastoma proliferation and undifferentiated state. Molecular Cancer Research 2020;18(1):68-78.
Yu X, Zhang Y, Wu B, Kurie JM, Pertsemlidis A. The miR-195 axis regulates chemoresistance through TUBB and lung cancer progression through BIRC5. Molecular Therapy – Oncolytics 2019;14:288-298.
Zhao Z, Partridge V, Sousares M,, Shelton SD, Holland CL, Pertsemlidis A, Du L. microRNA-2110 functions as an onco-suppressor in neuroblastoma by directly targeting Tsukushi. PLoS ONE 2018;13(12).
Li Y, Nowak C, Withers D, Pertsemlidis A, Bleris L. CRISPR-based editing reveals edge-specific effects in biological networks. The CRISPR Journal 2018;:286-293.
Du L, Zhao Z, Suraokar M, Shelton SS, Ma X, Hsiao TH, Minna JD, Wistuba II, Pertsemlidis A. LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget 2018;9:29601-29618.
Yu X, Zhang Y, Ma X, Pertsemlidis A. miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Letters 2018;427:85-93.
Yu X, Ma Z, Zhang Y, Zhao Z, Du L, Pertsemlidis A. miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death & Disease 2018;9(2).
Lin J, Zandi R, Shao R P, Gu J, Ye Y, Wang J, Zhao Y, Pertsemlidis A, Wu X, Roth J A, Ji L. A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling. Scientific Reports 2017;7(9029).
Zhao Z, Ma X, Li M, Sung D, Zhang M, Losiewicz MD, Chen Y, Pertsemlidis A, Yu X, Liu Y, Du L. A combined gene expression and functional study in neuroblastoma cell lines reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma. Oncotarget 2016;7(48):79372-79387.
Henry S, Kidner R, Reisenauer MR, Magedov IV, Kiss R, Mathieu V, Lefranc F, Dasari R, Evidente A, Yu X, Ma X, Pertsemlidis A, Cencic R, Pelletier J, Cavazos DA, Brenner AJ, Aksenov AV, Rogelj S, Kornienko A, Frolova LV. 5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells. European Journal of Medicinal Chemistry 2016;120:313-328.
Liu L, Pertsemlidis A, Ding LH, Story MD, Steinberg MH, Sebastiani P, Hoppe C, Ballas SK, Pace BS. A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease. Experimental Biology and Medicine 2016;241(7):706-718.
Zhao Z, Ma X, Sung D, Li M, Kosti A, Lin G, Chen Y, Pertsemlidis A, Hsiao TH, Du L. microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. RNA Biology 2015;12(5):538-554.
Masi M, Frolova L, Yu X, Mathieu V, Cimmino A, De Carvalho A, Kiss R, Rogelj S, Pertsemlidis A, Kornienko A, Evidente A. Jonquailine, a new pretazettine-type alkaloid isolated from Narcissus jonquilla quail, with activity against drug-resistant cancer. Fitoterapia 2015;102:41-48.
Borkowski R, Du L, Zhao Z, Kosti AK, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, White MA, Pertsemlidis A. Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D signaling. Cancer Research 2015;75(4):666-675.
Vaisnav M, Xing C, Ku H-C, Hwang D, Stojadinovic S, Pertsemlidis A, Abrams JM. Genome-wide association analysis of radiation resistance in Drosophila melanogaster. PLoS ONE 2014;9(8):104858-104858.
Du L, Zhao Z, Ma X, Hsiao TH, Chen Y, Young E, Suraokar M, Wistuba I, Minna JD, Pertsemlidis A. miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene 2014;33(34):4307-4315.
Zhao Z, Ma, Xiuye, Hsiao, Tzu-Hung, Lin, Gregory, Kosti, Adam, Yu, Xiaojie, Suresh, Uthra, Chen Y, Tomlinson GE, Pertsemlidis A, Du L. A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation. OncoTarget 2014;15;5(9):2499-2512.
Ahn, YH, Gibbons D, Chakravarti D, Creighton CJ, Rizvi Z, Adams H, Pertsemlidis A, Gregory P, Wright J, Goodall G, Flores E, Kurie J. Zeb1 drives prometastatic actin cytoskeletal remodeling by down-regulating miR-34a expression. Journal of Clinical Investigation 2012;:3170-3183.
Du L, Subauste MC, DeSevo C, Borkowski R, Baker M, Schageman JJ, Greer RM, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, Pertsemlidis A. miR-337-3p and its targets STAT3 and RAP1A modulate paclitaxel sensitivity in non-small cell lung cancers. PLoS ONE 2012;7(6):e39167-e39167.
Du L, Schageman JJ, Girard L, Hammond SM, Minna JD, Gazdar AF, Pertsemlidis A. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res 2010;29:75-75.
Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009;23(18):2140-2151.
